Novartis states that Vanrafia can slow the decline of kidney function in patients with IgA nephropathy.

LootboxPhobia · 2026-02-14T00:27:55+00:00

Novartis announces that its drug Vanrafia is effective in treating adult IgA nephropathy, with phase 3 clinical trials showing improvement in patients' kidney filtration rate. The drug is expected to receive accelerated approval in 2025 and plans to submit a traditional approval application in 2026.

LootboxPhobia

2026-02-14 00:27:55

Abstract generation in progress

Investing.com – Novartis announced on Friday that its drug Vanrafia has demonstrated efficacy in slowing the decline of kidney function in adults with IgA nephropathy (IgAN), a progressive autoimmune kidney disease.

The Swiss pharmaceutical company reported that phase three clinical trials showed Vanrafia improved the glomerular filtration rate in patients with the disease.

IgAN causes inflammation of the small filters in the kidneys and leads to excessive protein in the urine, a condition known as proteinuria.

Vanrafia received accelerated approval in the United States and China in 2025 for the treatment of proteinuria in adult IgAN patients.

Following these positive trial results, Novartis plans to submit a traditional approval application for the drug in 2026.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.